reduction Thank We we updates received immunology, approval we to program, itch on received in demonstrated important for expect the indication curing systemic had atopic all or highlight cyclosporine, recent not significant you, adult Rinvoq Jeff. dermatitis, and and across methotrexate, psoriatic be Rinvoq, this arthritis benefit safety moderate again We pipeline development clearance XX azathioprine, patients XX RA favorable strong stages of FDA biologics. in who also new In well In our severe option and such label the levels profile new responded our with to indications. updates. believe of skin both Rinvoq’s made to continued have and implemented progress for milligram based in regulatory other we an and and both atopic our adolescent agents, we in labels dermatitis year. risk as dermatitis, that to impressive atopic doses, several and important XXXX, and will milligram approval for treatment advancement
spondylitis, also have colitis, We in and applications axial Rinvoq for regulatory non-radiographic review ulcerative under ankylosing SpA.
Europe, we FDA in ulcerative ankylosing for in for in spondylitis, non-radiographic SpA fourth second SpA. quarter We colitis, expect the for the anticipate the axial year. second and non-radiographic approval approval the decision decisions of for month colitis and In ulcerative axial next half an quarter
patient induction indication completion where positive a impact expansion nearing major Rinvoq’s on Phase X Rinvoq. last Crohn’s program for refractory in clinical demonstrated announced of registrational Crohn’s remission the very We and recently first endoscopic which a We’re disease, results response program from top-line study, Rinvoq difficult-to-treat in is the population.
strong we We recently of first second psoriatic second regulatory Crohn’s expect study immunology, from level half option asset. arthritis, as in be the in efficacy new study an skin this provided Skyrizi from the patients. maintenance in the the psoriatic in an induction important received see indication results the registrational Also believe our for that expansion for XXXX. we effective and and Skyrizi half in positioned very submissions Skyrizi to on anticipated for X trials, will clearance of high Phase joint competitively year of this FDA the with arthritis Based treatment approval
applications and year. become impressive regulatory in have market, this Crohn’s in considerable need. in in for approval Skyrizi therapy disease believe where we the this month decisions also to under and unmet We our with seen potential continues Skyrizi expected program, next We’ve disease the new results be U.S. later there Crohn’s in Europe, to review an important has
and across standard-of-care are deeper core with novel progress immunology durable agents good developing goal with by very making We’re areas, early-stage significantly where well, providing more as the we the of responses. our our advancing pipeline
a ADC provide in delivering durable anti-TNF RA, ABBV-XXX is approach the Crohn’s as steroid a potential Our diseases to remission PMR potent disease. for has novel steroid and such that
see to ranging dose quarter the our expect of from Phase in data We RA fourth year. study preliminary X this in
to can provide Phase our dermatology, In early-stage proof-of-concept data efforts skin oral with also in that and Crohn’s see on disease focused clear We in developing durable XXXX. agents X PMR are responses. expect
result recently ABBV-XXX agonist, study on is RoRγT pure been psoriasis. antagonists, potential which Our X dose Phase the XXX inhibit inverse production in again IL-XX to skin effectively ranging to for to designed We’ve has inflammation. impact greater in a a more compared
to-date pipeline. we We non-small patients lung to less overall advanced an rates plus for based received these in median all of XX% options or on and response cell provides a where breakthrough continue designation FDA survival we’ve nonsquamous, line which therapy limited recently across XX%, one for Treatment Moving only of have stages seen Teliso-V make to our poor. in agent encouraging very immunotherapy progress chemo, patients exhausted to program. good are platinum-based year. oncology, is the second metastatic our targeted clinical single to who cancer, chemotherapy, typically of for than with Prognosis therapy results
corresponds no the represents While targeted pretreated each we exon cancer with year XX% are to patients, for promising of or lung non-small population highly metastatic therapies XX% nonsquamous, non-small skipping larger the who FDA cancer in XX% those stage with there incidence cell an exhibit c-Met of cell who c-Met. Phase a Patients lung group of U.S. patients have in approximately currently advanced In overexpressed been therapies mutations, saw about protein XX which the wild-type the in X% response XX,XXX EGFR, Teliso-V, received patients, of approved heavily to rate our approved, of harboring for the expressed much patients including by to c-Met MET X overexpression. study, X% objective X efficacy with specifically
approval and The lung an the non-small advanced of accelerated ongoing support second second-line stage study potential cell X Phase cancer. nonsquamous metastatic plus is has to in the
next year. this from data additional see study to expect We
recently next-generation payload potentially potent with ADC, and responses We which to patients our ABBV-XXX, more began deeper c-Met intermediate topoisomerase also for of expression. levels inhibitor in c-Met tumor the utilizes a drive high clinical both, program
a previously for year as oncology for late see or with for also will therapy of our untreated our designation. long-term Venclexta, the programs well for to and applications multiple from including We mutation the plan multiple in in program patients, CANOVA and opportunities X indication FDA to a results submit Phase received Venclexta for regulatory indications year the MDS to in We expect breakthrough drive accelerated from data we several results patients as myeloma. important this trial Venclexta expansion an important portfolio. in where help myeloma early growth t(XX;XX) first from for relapsed/refractory expansion ‘XX ‘XX this our represent approval Both MDS, in higher-risk half
the submission a best-in-class to epcoritamab, including follicular potential also B-cell generate monotherapy are progress the view support this We’ll We B to and expansion cell approval in strong third in of studies continue the which a potential has in has with several differentiated making second across very support year. epcoritamab the become to cohort malignancies early-stage to and see in the DLBCL, diffuse Phase quarter half data we accelerated bispecific good our lymphomas. that CDXxCDXX for X from where data
standard-of-care third-line Phase a maturing combination additional multiple myeloma. well from BCMA-CDX year DLBCL additional best-in-class plan follicular and several including initiate also lines lymphoma as initiate this efficacy, to in lymphoma for for studies a and We X our has in be in as with and Phase plan ongoing combination to believe therapy have X novel therapy. lines trials as rituximab in of multiple interval in study bispecific combinations, dosing also we multiple relapsed/refractory in and see both safety year, this data year, earlier monotherapy expansion in multiple we’ll can across the with studies in differentiated cohort potential B-cell our and X Revlimid. agents This studies to of be We We and myeloma. relapsed/refractory on ABBV-XXX, Phase later diffuse
We good strong which improved disease provide where and myelofibrosis, believe Navitoclax clinical in also we’ve to make will to mid-stage seen patients. progress the we for supporting lead outcomes our has durable data to view modification, potential Navitoclax with continue that
anticipated the readout a near end regulatory data in XXXX. submissions Phase the year, of expect and next first X with of We half approval
as positioned an for the benefit-risk data depressive believe the well. preparing in be Vraylar treatment Moving completed potential strong we program, events clinical and to the recently we pipeline in disorder. adjunctive with has are adjunctive an totality to our disorder. FDA submit depressive Vraylar as We discussions application neuroscience, of the profile competitively important major our Based for XXXX demonstrated where major expect as to and on several for the treatment
Phase proved of delivery decision end the to year. the this to our advanced and our regulatory an year migraine prevention XXX in subcutaneous track both believe fluctuations plan chronic on oral We’ve in of quarter Europe anticipated also current U.S. advanced the levodopa/carbidopa the the our submit for Qulipta approval Phase and half with U.S. Europe, summer, submission program in innovative studies, Parkinson’s registration-enabling X expect motor transformative to to levodopa/carbidopa approval applications a system expect we decisions potentially disease. half treatment our expected first XXXX. remain quarter for superior this new early see ABBV-XXX, X And data for in in of by regulatory completed in represents treatment We both, our In in approval first improvement in the and in system a this submit delivery the first population, and novel and in our reducing first to we later the of with We options. XXXX. decisions applications
we and milestones drugs our includes indication from additional important on for over Rob? anticipate call remain programs. summary, data our programs in our assets as for numerous to all continuing to the that, on in clinical Rob proof-of-concept important stages regulatory well across for This NME several comments late-stage turn regulatory performance expansion and So, XXXX. readouts outlook. XXXX and focused on as data With financial key I’ll fourth actions execute and and early-stage pipeline of pipeline quarter our on-market
